Fredrik Sjövall
Chairman of the Board
Chairman of the Board since 2020 (board member since 2018). Trained civil engineer in automation technology and a master’s degree in business development.
Born: 1980
Experience: Fredrik has 15 years of experience in positions as CEO and Chairman of companies in the Life Science industry. Previous positions include CEO of Inhalation Sciences AB, PharmaSurgics AB (now Promore Pharma AB) and Hemcheck AB.
Ongoing assignments: Chairman of the Board of Ziccum AB, Monivent AB, and Emollivet AB. Board member of Axelero AB and Phargentis AB and CFO at Atley Solutions AB.
Previous assignments in the last five years: Chairman of Hemcheck Sweden AB, Inhalation Sciences Sweden AB and Ectin Research AB.
Holding in the Company: 3,000,000 shares and 750,000 warrants (TO 2).
Fredrik Sjövall is independent in relation to the Company and the Company’s largest owner.
Ola Flink
Board member
Board member since 2017 (Chairman of the Board 2017-2020). Pharmacy degree.
Born: 1944
Experience: Ola has nearly 50 years of experience from the pharmaceutical industry, including Astra Zeneca, ACO Pharmaceuticals, and as a consultant regarding drug development and experience as an investor in Life Science. Ola is a board member (and former chairman) of Asarina Pharma AB (publ.), listed on Nasdaq First North.
Ongoing assignment: Chairman of Pens. Pharmaceutical Association. Board member of Asarina Pharma AB (publ.) and in Ola Flink Consulting AB. Member of the Nomination Committee for Brf Tullstugan 3.
Previous assignments in the past five years: Board member of Umecrine Cognition AB, Marbileads AS Norway, and Asarina Pharma AB (publ).
Owns more than five percent of the shares in: Ola Flink Consulting AB.
Holding in the Company: 3,422,977 shares and 750 000 warrants (TO 2).
Ola Flink is independent in relation to the Company and the Company’s largest owner.
Denis Angioletti
Board member
Board member since 2020. Degree in Pharmaceutical Chemistry and Technology from the University of Milan.
Born: 1968
Experience: Denis has 25 years of experience in the pharmaceutical industry. After an initial period in pharmaceutical development, most of his career has been in Sales, Marketing and Business Development positions in the pharmaceutical industry, mainly in API manufacturing companies, with responsibility roles for generic APIs and for CDMO. Most recently, between 2013 and 2017, Denis was Vice President Pharmaceuticals at Summit Pharmaceutical Europe. Since 2017, Denis has held the post of CCO at Cerbios Pharma AG.
Other assigments: CCO at Cerbio-Pharma SA.
Holdings in the Company: –
Denis Angioletti is currently CCO at Cerbios-Pharma SA and is therefore to be considered dependent in relation to one of the Company’s major shareholders. He is independent of the Company and its management.
Gunilla Lundmark
Board member
Board member since 2019.
Born: 1963
Experience: For more than 25 years, Gunilla has been active in leading positions within the Life Science sector, with experience in development, manufacturing, sales and business development, amongst other areas. Gunilla is currently CEO of Uppsala University Invest AB, which invests at early stage in promising and innovative companies with great growth potential. Most recently, Gunilla was CEO of Pharmanest AB, where she led the development from idea to commercialization phase. Before that, Gunilla was vice president at Q-Med AB. Gunilla began her career at Pharmacia & Upjohn.
Ongoing assignment: CEO of Uppsala Universitetet Invest AB. Board member of Chordate Medical Holding AB (publ), Chordate Medical AB, Uppsala Innovation Center AB, Institute for Personnel and Business Development AB, Uppsala University Projekt AB, Uppsala Universitetet Research Intellectual Property AB, Linéa Capital I AB and Combigene AB.
Holdings in the Company: 150 000 shares.
Gunilla Lundmark is independent in relation to the Company and the Company’s largest owner.
Otto Skolling
Board member
Board member since 2020.
Born: 1961
Experience: Otto holds a Master’s degree in Chemical Engineering from the Royal Institute of Technology in Stockholm. He has 20 years of broad experience in the pharmaceutical and medical technology industries, including product development, business development and project management that he earned through leading positions at Novozymes, Siemens Life Support Systems and Pharmacia & Upjohn.
Other assignments: Responsible for Business Development at Nanexa, Chief Business Officer in Asarina Pharma AB, board member in Respinor AS, CEO and board member in Isles of Wines AB, CEO and board member in Pharmor AB and chairman in Chordate Medical AB.
Holdings in the Company: 5,159,360 shares and 1,289,840 warrants (TO 2).
Otto Skolling is considered to be independent of the Company and its management. He is also independent of the company’s major shareholders.